MimoPools™

The latest innovation from the experts in PepSets™ Peptide Library synthesis, MimoPools are uniquely suited to cutting-edge research applications.


These modern peptide libraries are aliquoted and pooled into one convenient peptide mix for maximum manouvereability.

Expanded Applications

MimoPools™ takes standard peptide library screening studiesfurther with critical applications in antigen-specific T-cell response studies, epitope mapping, and immune monitoring.


Pivotal in the continuing worldwide SARS-CoV-2 research, strategically synthesised peptide pools can contain specific sequences for mutations in key proteins or complete protein sequences for each variant.

High Quality Peptides

MimoPools™ are produced using the same validated peptide library synthesis procedureswe’re known for. Our stringentquality control measures guarantee identity and purity, and all peptide pools are supplied with a Certificate of Analysis and Mass Spectrometry data. 


Designed For Success

MimoPools™ are expertly designed on a case-by-case basis to include pre-synthesised catalogue peptides or made-to-order sequences, with all of the modification and customisation option typical of a standard peptide library.


The design of truncated peptide pool has been optimised for T-cell studies by the inclusion of four strategically truncated lengths of the same sequence in each pool.

MimoPools™ are available as-synthesised or purified up to 95%. These peptide pools are supplied as freeze-dried aliquots, offering long-term stability, and allowing MimoPools™ to be used and reused at your convenience.

Contact us today for a quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

✉ useast@mimotopes.com

✉ uswest@mimotopes.com



asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Tackling insulin prices Go to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: CommentGo to article: Why did the cannabis industry blossom during the pandemic?Go to article: Negative AdCom vote for Amylyx’s ALS drug AMX0035, but hope remainsGo to article: Will Russia’s invasion affect biopharmaceutical licensing agreements?Go to article: Fall from grace? What 2022 may have in stock for biopharmaceutical SPACsGo to article: BEA TechnologiesGo to article: In DepthGo to article: Insulin pricing: could an e-commerce approach cut costs?Go to article: Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs Go to article: Big pharma’s gradual retreat on clinical trials in Russia Go to article: Covid-19, flu combo vaccines an advance but with rollout quandariesGo to article: FDA shows unease about marketing approval applications based on single-country tGo to article: In DataGo to article: How big is the gender pay gap in the pharma industry in Britain?Go to article: Where is trade most likely to be disrupted in pharma from the Russian invasion oGo to article: Big data innovation among pharma companies dropped off in the last quarterGo to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue